Teva's Migraine Treatment Effective In Patients With Co-Morbid Depression

• Teva Pharmaceutical Industries Ltd (NYSE: TEVA) announced the results of two studies presented at the Migraine Trust International Symposium (MTIS).

• The data demonstrate the efficacy of Ajovy (fremanezumab) in migraine patients who also experience depression or anxiety.

• Ajovy is indicated to prevent migraine in adults with at least four migraine days per month.

• In both studies, quarterly and monthly dosing of fremanezumab demonstrated efficacy in reducing monthly migraine attacks by more than 50% compared to placebo.

• Results at three months showed that 32% of patients on quarterly fremanezumab and 36% on monthly fremanezumab achieved a ≥ 50% reduction in monthly migraine days compared to 19% of those taking placebo.

• Depression and anxiety are common co-morbidities experienced by around half of all patients with migraine.

• Ajovy has been shown to be an effective migraine preventive treatment in a range of patients, including those with depression and anxiety.

• Price Action: TEVA shares are up 1% at $8.92 on the last check Thursday.

See more from Benzinga

• HUTCHMED Cancer Med Cuts Death Risk By 34% In Metastatic Colorectal Cancer

• A Biotech's Stock Just Hit Year High. This Analyst Expects It To Jump Another 16%

• GameStop (NYSE:GME) – Apes Have Locked Up This Many Million GameStop Shares On DRS: What's Going On?

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.